Selection of antiviral drugs for patients with hepatitis B virus-associated hepatocellular carcinoma
10.3969/j.issn.1001-5256.2022.11.004
- VernacularTitle:HBV相关肝细胞癌患者抗病毒药物的选择
- Author:
Mingyang FENG
1
;
Hui WANG
1
Author Information
1. Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Publication Type:Discussions by Experts
- Keywords:
Hepatitis B Virus;
Carcinoma, Hepatocellular;
HBV Reactivation;
Antiviral Agents
- From:
Journal of Clinical Hepatology
2022;38(11):2452-2456
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) infection is a key risk factor for the development and progression of hepatocellular carcinoma (HCC) and it promotes the progression of HCC by inducing liver fibrosis, genetic and epigenetic alterations, and the expression of active virally encoded proteins. Many studies have confirmed the influence of viral status on the prognosis of HCC, and effective antiviral therapy can help prevent or delay the recurrence of HBV-associated HCC, increase the overall survival time of patients undergoing radical or systemic, and improve the prognosis after multimodality therapy. Therefore, correct selection of antiviral drugs is crucial for the antiviral treatment of patients with HBV-associated HCC. This article briefly reviews the selection of antiviral drugs for patients with HBV-associated HCC, so as to provide a reference for clinical practice.
